While promising, be VERY skeptical about efficacy claims of these early stage research drugs.

Tons of drugs in the pipeline that goes after these promising receptor targets. PD-1/PD-L1, CD47, CD40 (as mentioned in the article) etc. Keytruda (PD-1) is an incredible success both clinically and commercially, but there are many many other drugs buried in the clinical trial cemetery that initially showed promising results.

Medicine is really hard.

> but there are many many other drugs buried in the clinical trial cemetery that initially showed promising results

Mot many that showed such dramatic results across different types of cancer with very low toxicity.

Even if it turns out this drug kills 10% of patients outright, it would still be useful.